US · Healthcare · Biotechnology
EPS came in at 0.30 against a street estimate of 0.33 — a miss of 9.1%.
Analysts rate Pharming Group NV a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $35.10.
| Fund | Stake |
|---|---|
| MAC Alpha Capital Management, LP | 3.04% |
| Silverberg Bernstein Capital Management LLC | 0.05% |
| Crossmark Global Holdings, Inc. | 0.02% |
| Citadel Advisors Llc | 0.02% |
| Morgan Stanley - Brokerage Accounts | 0.02% |
| SmartHarvest Portfolios, LLC | 0.01% |
| Knoll Capital Management LP | 0.01% |
| Silver Grove Financial Group, Inc. | 0.00% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue rose 21% year over year to US$117.6 million, from US$97.3 million. • Operating profit increased 89% to | 2026-10-27 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue is expected to be approximately US$117.6 million, up 21% from US$97.3 million in the third quarte | 2026-10-22 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Pharming reported positive topline results from a Phase II trial of leniolisib in genetically identifiable primary immunodeficienc | 2026-10-14 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • No financial results, operating metrics, or valuation figures were provided in this announcement. • The CEO transition took effec | 2026-09-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • The U.S. FDA accepted Pharming’s supplemental New Drug Application (sNDA) for lower doses of Joenja® (leniolisib) in children with | 2026-09-25 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Pharming reported positive topline results from a Phase II trial of leniolisib in genetically defined primary immunodeficiencies ( | 2026-09-22 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • FDA approved Joenja® (leniolisib) for children with activated phosphoinositide 3-kinase delta syndrome (APDS) aged 4 to 11 years w | 2026-09-11 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Pharming announced the commercial launch of Joenja (leniolisib) in Japan on August 13, 2026. • Joenja is available in Japan for | 2026-08-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pharming Group NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.